

# A hierarchical whole body modeling approach elucidates the link between in vitro insulin signaling and in vivo glucose homeostasis

Elin Nyman, Cecilia Brännmark, Robert Palmér, Jan Brugård, Fredrik H Nyström, Peter Strålfors, Gunnar Cedersund

## Supplemental Figures S1-S5



**Figure S1. The model structures within the hypothesis** *Ma.* The corresponding differential equations can be found in the simulation files for each model. All chosen model structures only deal with the essential dynamics, and are no attempts to include all known reactions or components of the system. ins, insulin; IR, insulin receptor; IR-P, phosphorylated IR; IRins, IR with bound insulin; IRi-P, internalized and phosphorylated IR; IRi internalized IR; IRS1, insulin receptor substrate 1; IRS1-P, phosphorylated IRS1; X and X-P, non-active and active form of an unknown protein; PKB, protein kinase B; PKB-P, phosphorylated PKB; GLUT1, glucose transporter 1; GLUT4, glucose transporter 4; GLUT-pm, GLUT4 translocated to the plasma membrane. *Ma*7 from (1).



**Figure S2.** The model structures within the hypotheses *Mb*, *Mc* and *Md*. Red, dashed lines and text denotes *in vitro/vivo*-differences. All other notations as in Figure S1. The corresponding differential equations can be found in the simulation files for each model. All chosen model structures only deal with the essential dynamics, and are no attempts to include all known reactions or components of the system.






Figure S3. Core-prediction . Core-prediction of glucose uptake with 5.0 mM glucose from model Ma6.





Simulated results are depicted as blue solid lines (one line for each extreme acceptable parameter-set), and experimental data are depicted as red, filled circles with error-bars (± one SE). A) IR phosphorylation in response to 100 nM insulin. Experimental data from isolated adipocytes. B) IRS1 phosphorylation in response to 100 nM insulin. Experimental data from isolated adipocytes. C) IRS1 phosphorylation in response to first 1.2 nM at 0 min, and then 10 nM insulin at 4 min. Experimental data from isolated adipocytes. D) IRS1 phosphorylation in response to 10 nM insulin. Experimental data from isolated adipocytes. E) Dose-response for glucose uptake in response to increasing concentrations of insulin. Experimental data from isolated adipocytes. F) Glucose uptake by the adipose tissue in response to a meal. Experimental data from the Dalla Man-model.





Simulated results are depicted as blue solid lines (one line for each extreme acceptable parameter-set), and experimental data are depicted as red, filled circles with error-bars ( $\pm$  one SE). A) IR phosphorylation in response to 100 nM insulin. Experimental data from isolated adipocytes. B) IRS1 phosphorylation in response to 100 nM insulin. Experimental data from isolated adipocytes. C) IRS1 phosphorylation in response to first 1.2 nM at 0 min, and then 10 nM insulin at 4 min. Experimental data from isolated adipocytes. D) IRS1 phosphorylation in response to 10 nM insulin. Experimental data from isolated adipocytes. E) Dose-response for glucose uptake in response to increasing concentrations of insulin. Experimental data from isolated adipocytes. F) Glucose uptake by the adipose tissue in response to a meal. Experimental data from the Dalla Man-model.

# Supplemental Tables S1-S2

### TABLE S1

Model rejections for different degrees of freedom and levels of significance

			Dataset Z <sub>1</sub>			
	Degrees of freedom	34	34	31	28	36
	Level of significance	1%	5%	5%	5%	1 %
Ma1	Simple model	OK	Rejected			
Ma2	Ma1 + positive feedback (PKB $\rightarrow$ IRS1)	OK	ОК	OK	OK	Rejected
МаЗ	Ma1 + negative feedback (PKB $\rightarrow$ IRS1)	OK	Rejected			
Ma4	<i>Ma</i> 1 + Hill equation (GLUT4 glucose uptake)	OK	ОК	OK	Rejected	
Ma5	<i>Ma</i> 1 + basal translocation of GLUT4	OK	Rejected			
Ma6	Ma1 + Mifa (2)	OK	ОК	OK	OK	Rejected
Ma7	Sedaghat model (1)	OK	Rejected			

### TABLE S2

Model rejections for different degrees of freedom and levels of significance

			Data	set Z <sub>2</sub>	
	Degrees of freedom	36	36	33	30
	Level of significance	1%	5%	5%	5%
Basal GLUT4 translocation hypothesis					
Mb1	Ma1 + basal-translocation	Rejected			
Mb2	Ma2 + basal-translocation	OK	Rejected		
Mb3	Ma6 + basal-translocation	Rejected			
Blood-flow hypothesis					
Mc1	Ma1 + blood-flow	OK	Rejected		
Mc2	Ma2 + blood-flow	OK	Rejected		
Multiple in vivo/vitro-differences					
<i>Md</i> 1	<i>Mb</i> 1 + <i>in vivo/vitro-</i> different Km GLUT4	ОК	ОК	Rejected	
Md2	<i>Mb</i> 1 + <i>in vivo/vitro-</i> different Vmax GLUT4	OK	ОК	ОК	Rejected
Md3	Mb1 + Mc1	OK	OK	OK	OK

### Supplemental Methods

### Principles of constructing and simulating a model using module constraints

Consider model structure *Ma*1 in Figure S1. We assume that all reactions follow mass action kinetics and act through simple multiplication. We also assume that the basal activation is given by a basal activation of the insulin receptor. With these assumption, the set of differential equations become

$$\begin{split} & I\dot{R} = k1b \cdot IRp - k1f \cdot IR \cdot insulin - k1basal \cdot IR \\ & I\dot{R}p = -k1b \cdot IRp + k1f \cdot IR \cdot insulin + k1basal \cdot IR \\ & I\dot{R}S = k2b \cdot IRSp - k2f \cdot IRS \cdot IRp \\ & I\dot{R}Sp = -k2b \cdot IRSp + k2f \cdot IRS \cdot IRp \\ & P\dot{K}B = k3b \cdot PKBp - k3f \cdot PKB \cdot IRSp \\ & P\dot{K}Bp = -k3b \cdot PKBp + k3f \cdot PKB \cdot IRSp \\ & GL\dot{U}T4 = k4b \cdot GLUT4pm - k4f \cdot GLUT4 \cdot PKBp \\ & GL\dot{U}T4pm = -k4b \cdot GLUT4pm + k4f \cdot GLUT4 \cdot PKBp \end{split}$$

The total amounts of the proteins are unknown and we thus use relative amounts to describe the initial conditions of the states. All model simulations are initiated by a steady-state simulation to assure that the system is at rest and to allow for different ratios of the proteins for different parameter values. The initial values are denoted

IR(0) = 10 IRp(0) = 0 IRS(0) = 10 IRSp(0) = 0 PKB(0) = 10 PKBp(0) = 0 GLUT4(0) = 10GLUT4pm(0) = 0

The parameters of the model are

k1basal k1f k1b k2f k2b k3f k3b k4f k4b k<sub>glut1</sub> k<sub>glut4</sub> Km<sub>G1</sub> Km<sub>G4</sub>

To simulate the model to mimic the different diagrams in the dataset Z1 we use both the module constraints and the different experimental settings. The input constraints of the module – insulin and glucose – are functions of time

 $insulin = f_1(t)$  $glucose = f_2(t)$ 

A simulation of the model with the input constraints as input signals must fit the output constraint, i.e. the glucose uptake

 $glucose \ uptake = k_{glut1} \cdot \frac{glucose}{Km_{G1} + glucose} + k_{glut4} \cdot \frac{glucose}{Km_{G4} + glucose} \cdot GLUT4pm$ 


Insulin and glucose are also kept at values according to the performed experiments to simulate these and to compare with glucose uptake but also with IRp, IRSp and PKBp.

Recall that all chosen models only deal with the essential dynamics, and are no attempts to include all known reactions and components of the system.

All model equations are found in the supplemental file ModelFiles.zip and all simulations of the models are found in the supplemental file SimulationFiles.zip.


## Supplemental Description of Model $M^3$

The final model  $M^3$  consists of three levels: whole-body level, adipose tissue level, and insulin binding level. A schematic overview of the system is found below. Here we present the model equations for all these levels and show how we merge the levels into one multi-level model. The connections between the whole-body level and the other levels are in **red**, and connections between the adipose tissue level and the insulin binding level in **green**.



#### The whole-body level

The whole-body level is taken from (3) with one small modification. We sub-divided the insulinresponding glucose uptake module in two parts; muscle and adipose tissue, with static 80/20 proportions. We did not change the values of the parameters. A schematic overview of the whole-body level is given by the following figure.



#### Glucose kinetics

The glucose kinetics module describes the dynamic change in glucose concentration in the two compartments plasma and tissues. More motivations for these equations are given in (3). The same holds for all equations relating to the whole-body level.

$$d/dt(G_p) = EGP+Ra-E-U_ii- G_p(0) = 178 k_1*G_p+k_2*G_t d/dt(G_t) = (-U_id)+k_1*G_p- G_t(0) = 135 k_2*G_t$$

 $G = G_p/V_G$ 

G_p	glucose mass in plasma and rapidly equilibrating tissues
G_t	glucose mass in slowly equilibrating tissues
G	plasma glucose concentration

#### Insulin kinetics

The insulin kinetics module describes the dynamic changes in insulin concentration in the two compartments plasma and liver.

$d/dt(I_l) = (-m_1*I_l) - $	$I_1(0) = 4.5$
<pre>m_3*I_l+m_2*I_p+S d/dt(I_p) = (-m_2*I_p)-     m 4*I p+m 1*I l</pre>	$I_p(0) = 1.25$
$I = I_V / U_I$	
$HE = (-m 5 \times S) + m 6$	
m_3 = HE*m_1/(1-HE)	

I_p	insulin mass in plasma
I_l	insulin mass in liver
HE	hepatic extraction

### Glucose Rate of Appearance (gastrointestinal tract)

In the gastrointestinal tract the glucose enter the system and travel through three compartments before it appears in the plasma.

d/dt(Q_sto1) = -k_gri*Q_sto1	$Q_{stol}(0) = 78000$
$d/dt(Q_sto2) = -k_empt*Q_sto2$	$Q_{sto2}(0) = 0$
+k_gri*Q_sto1	
$d/dt(Q_gut) = -k_abs*Q_gut$	$Q_gut(0) = 0$
+k_empt*Q_sto2	
Q_sto = Q_sto1+Q_sto2	
Ra = f*k_abs*Q_gut/BW	
$k_{empt} = k_{min+(k_{max}-k_{min})/2*(tanh(a$	*(Q_sto-b*D))-tanh(c*(Q_sto-
d*D))+2)	

Q_stol	first stomach compartment
Q_sto2	second stomach compartment
Q_gut	mass of glucose in the intestine
Q_sto	amount of glucose in the stomach
Ra	glucose rate of appearance

### Endogenous Glucose Production (liver)

The glucose production in the liver is dependent on glucose in the plasma, a delayed insulin signal from the plasma and insulin in the portal vein.

d/dt(I_1)	$= -k_i \star (I_1-I)$	$I_1(0) = 25$
d/dt(I_d)	$= -k_i \star (I_d-I_1)$	$I_d(0) = 25$

 $EGP = k_p1-k_p2*G_p-k_p3*I_d-k_p4*I_po$ 

I_1	helping state to describe a delayed insulin signal
I_d	helping state to describe a delayed insulin signal
EGP	endogenous glucose production

#### Glucose Uptake

The glucose uptake by the insulin sensitive tissues is a sum of glucose uptake in muscle and adipose tissue. Recall that we mark a connection between the whole-body level and the other levels with **red**.

U\_id = U\_idm+vglucoseuptake

U\_id insulin dependent glucose uptake

#### Glucose Uptake (muscle tissue)

Glucose is taken up in the muscle tissue and the uptake depends on the interstitial insulin and the glucose tissue concentrations.

d/dt(**INS**) = (-p\_2U\*INS)+p\_2U\*(I- INS(0) = 0 I\_b)

U\_idm = 0.8\*(V\_m0+V\_mX\*INS)\*G\_t/(K\_m0+G\_t)

INS	insulin in the interstitial fluid
U_idm	insulin dependent glucose uptake by the muscle tissue

#### Glucose Uptake (adipose tissue)

The glucose uptake by the adipose tissue (**vglucoseuptake**) is described below in the adipose tissue level, in the section Glucose uptake dynamics.

#### Insulin Secretion (beta cells)

Insulin is produced and secreted from the beta cells in the pancreas. The amount of insulin that is secreted is calculated from the glucose concentration in the plasma

d/dt(I_po) = (-gamma*I_po)+S_po	$I_po(0) = 3.6$
d/dt(Y) = -alpha*(Y-beta*(G-	Y(0) = 0
G_b))	
S = gamma*I_po	
$S_po = Y+K*(EGP+Ra-E-U_ii-k_1*G_p+k_2*$	G_t)/V_G+S_b

_		C · 1 ·	• .1	. 1	•
1 no	omount (	st incuilin	in tha	nortal	VAIN
I_po	amount of	л шъщни	III UIC	DUILAI	VUIII
- <u>-</u> r				r	

Y helping state to calculate the insulin secretion

S insulin secretion to beta cells

S\_po insulin secretion to the portal vein

**Glucose Renal Excretion** 

When the concentration of glucose in the blood is high glucose will be excreted to the kidneys. However, this will not happen for healthy individuals so we set the renal excretion to 0.

E = 0

#### renal excretion

#### Parameters

We use the parameters that have been determined and further described in (3).


V_G	1.88	dl/kg
k_1	0.065	/min
k_2	0.079	/min
V_I	0.05	l/kg
m_1	0.190	/min
m_2	0.484	/min
m_4	0.194	/min
m_5	0.0304	min <sup>-</sup> kg/pmol
m_6	0.6471	dimensionless
HE_b	0.6	dimensionless
k_max	0.0558	/min
k_min	0.0080	/min
k_abs	0.057	/min
k_gri	0.0558	/min
f	0.90	dimensionless
а	0.00013	/mg
b	0.82	dimensionless
С	0.00236	/mg

0.010	
0.010	dimensionless
2.70	mg/kg/min
0.0021	/min
0.009	mg/kg/min per pmol/l
0.0618	mg/kg/min per pmol/kg
0.0079	/min
1	mg/kg/min
2.50	mg/kg/min
0.047	mg/kg/min per pmol/l
225.59	mg/kg
0.0331	/min
2.30	pmol/kg per mg/dl
0.050	/min
0.11	pmol/kg/min per mg/dl
0.5	/min
78	kg
78000	mg
	0.0021 0.009 0.0618 0.0079 1 2.50 0.047 225.59 0.0331 2.30 0.050 0.11 0.5 78

#### The adipose tissue level

The adipose tissue level is developed by us in this study. We have tested a number of hypotheses to find a minimal model (Md3), partly based on (2), that can explain all our experimental data and fit the module constraints from the whole-body level. This hypothesis we have then expanded to include interesting proteins within the adipocyte. The parameters of this level were optimized to gather all the acceptable parameter sets. A schematic overview of the adipose tissue level is the following figure.

Е



#### IRS1 and X dynamics

The insulin receptor substrate is activated by phosphorylation from active insulin receptor states from the insulin binding level described below. Also, positive feedbacks from downstream proteins further activate IRS1. The unknown protein X is activated by IRS1iP and act as a negative feedback to the insulin receptor. This part of the adipose tissue level is adopted from and further described in (2), with the difference that we have now replaced the insulin receptor states with corresponding ones from the insulin binding level. Recall that we mark connections between the adipose tissue level and the insulin binding level with green.

d/dt(IRS1) = v2b-v2f	IRS1(0) = 9.99982
d/dt(IRS1iP) = -v2b+v2f	IRS1iP(0) = 0.00018
d/dt(X) = v3b-v3f	X(0) = 9.92463
$d/dt(X_P) = -v3b+v3f$	$X_P(0) = 0.07537$
v2f = k21*IRS1*(( <b>r1x2+r11x2+r1x22+</b> )	<b>r1x22d+r11x22+rPbasal</b> )+k22* <b>rendP</b> )
*(1+k23*PKC_P+k24*mTOR)	
v2b = k2b*IRS1iP	
v3f = k3f*X*IRS1iP	
$v3b = k3b*X_P$	
TDS1 insulin recentor substrate_1	

IRSI	insulin receptor substrate-1
IRS1iP	phosphorylated (active) form of IRS1
Х	downstream intermediate which dephosphorylates IR in its active form
X_P	active form of X

#### PI3K and PDK1 dynamics

PI3K is activated by IRS1 and subsequently PDK1 is activated by PI3K. We assume that the activations follow simple mass-action kinetics.

<pre>d/dt(PI3K) = v4b-v4f d/dt(PI3K_) = -v4b+v4f d/dt(PDK1) = v5b-v5f d/dt(PDK1_) = -v5b+v5f</pre>	PI3K(0) = 9.97578 PI3K_(0) = 0.02422 PDK1(0) = 8.65877 PDK1_(0) = 1.34123
<pre>v4f = k4f*PI3K*IRS1iP v4b = k4b*PI3K_ v5f = k5f*PDK1*PI3K_ v5b = k5b*PDK1_</pre>	

PI3K phosphatidylinositol 3-kinases

PI3K\_active form of PI3KPDK13-phosphoinositide dependent protein kinase-1PDK1\_active form of PDK1

#### PKC and PKB dynamics

Both PKB and PKC are activated by PDK1 in its active form. We assume that the activations follow simple mass-action kinetics.

<pre>d/dt(PKC) = v6b-v6f d/dt(PKC_P) = -v6b+v6f d/dt(PKB) = v7b-v7f d/dt(PKB_P) = -v7b+v7f</pre>	PKC(0) = 3.60284e-05 PKC_P(0) = 9.99996 PKB(0) = 9.90193 PKB_P(0) = 0.09807
<pre>v6f = k6f*PKC*PDK1_ v6b = k6b*PKC_P v7f = k7f*PKB*PDK1_ v7b = k7b*PKB_P</pre>	
PKC protein kinase C	
PKC_Pphosphorylated (active) form of PKC	
PKB protein kinase B	

PKB_P	phosphorylated (active) form of PKB
-------	-------------------------------------

#### mTOR and GLUT4 dynamics

mTOR is activated by PKB in its active form. The glucose transporters (GLUT4) are moving from the cytosol to the plasma membrane both at a basal level and when activated by PKB and PKC. We assume that the activations follow simple mass-action kinetics.

d/dt(mTOR) = v8b-v8f	mTOR(0) = 0.02019
$d/dt(mTOR_) = -v8b+v8f$	$mTOR_(0) = 9.97981$
d/dt(GLUT4_C) = v9b-v9f	$GLUT4_C(0) = 9.99317$
d/dt(GLUT4_M) = -v9b+v9f	$GLUT4_M(0) = 0.00683$
v8f = k8f*mTOR*PKB_P	
$v8b = k8b*mTOR$ _	
$v9f = k91*GLUT4_C*PKC_P+k92*GLUT4_C*PK$	B_P+k5BasicWb*GLUT4_C
$v9b = k9b*GLUT4_M$	

mTOR	mammalian target of rapamycin
mTOR_	active form of mTOR
GLUT4_C	glucose transporter 4 in vesicles in the cytosol
GLUT4_M	glucose transporter 4 in the plasma membrane ready to take up glucose

#### Glucose uptake dynamics

The glucose uptake in the adipose tissue comes in this model from three terms; glucose transporter 1 (noninsulin dependent), glucose transporter 4 (insulin-dependent through the insulin signaling cascade and thus through GLUT4), and blood flow (directly insulin-dependent). We assume that the glucose uptake also depends on the interstitial glucose concentration ( $G_t$ , from the whole-body level) and that the dependency is saturated.

#### vglucoseuptake =

```
k_glut1*G_t/(KmG1+G_t)+k_glut4*GLUT4_M*G_t/(KmG4+G_t)+kbf*(INS+5)
```


**Parameters** 

The parameters of the adipose tissue level were optimized to find the acceptable solutions. The following parameters are part of this level.

k21	k22	k23	k24	k2b	k3f	k3b	k4f	k4b
k5f	k5b	k6f	k6b	k7f	k7b	k8f	k8b	k91
k92	k9b	k5Basic	k5BasicWb	k_glut4	k_glut1	KmG1	KmG4	kbf

#### The insulin binding level

The insulin binding level is taken from (4). We took the model structure and merged with our adipose tissue module. The parameters in (4) were fitted to data from other cell types so we used optimization to gather the acceptable parameter sets. A schematic overview of the insulin binding level is found below.



#### The inactive receptor states

The following insulin receptor states can bind one or two insulin molecules, or be unbound. The states that bind at least one insulin molecule can be activated.

d/dt(r0) = -R1 - R2 + R5 + R8 + R37 -	r0(0) = 9.96820
R46+R47	
d/dt(r1) = +R1-R3-R5-R6-	r1(0) = 0.02214
R9+R12+R15+R19	
d/dt(r2) = +R2-R4-R7-R8-	r2(0) = 0.00935
R10+R13+R16+R22	
d/dt(r11) = +R3-R12-R17+R26	r11(0) = 1.22887e-005
d/dt(r12) = +R4+R6-R13-R15-R18-	r12(0) = 1.03764e-05
R20+R27+R28	
d/dt(r22) = +R7-R16-R21+R29	r22(0) = 2.18683e-06

r0	inactive receptor state with no insulin bound
rl	inactive receptor state with 1 insulin molecule bound to site 1
r2	inactive receptor state with 1 insulin molecule bound to site 2
r11	inactive receptor state with 2 insulin molecules bound to site 1
r12	inactive receptor state with 2 insulin molecules bound to site 1 and 2 respectively
r22	inactive receptor state with 2 insulin molecules bound to site 2

<u>The active receptor states</u> When insulin is bound to the receptor it can be activated and also phosphorylated. The active states activate IRS1 at the adipose tissue level (above).

d/dt( <b>r1x2</b> ) = +R9+R10-R11-R14-	r1x2(0) = 1.36476e-06
R19-R22-	
R23+R24+R25+R34-R39	
d/dt( <b>r11x2</b> ) = +R11+R17+R20-R24-	r11x2(0) = 1.51514e-09
R26-R28-R31+R36-R40	
d/dt( <b>r1x22</b> ) = +R14+R18+R21-R25-	r1x22(0) = 6.39352e-010
R27-R29-R30-	
R32+R33+R35-R41	
d/dt( <b>r1x22d</b> ) = +R23+R32-R33-R34-	r1x22d(0) = 5.59231e-020
R42	
d/dt( <b>r11x22</b> ) = +R30+R31-R35-R36-	r11x22(0) = 1.78726e-014
R43	

r1x2	active receptor state with 2 insulin molecules bound to site 1 and 2 respectively
r11x2	active receptor state with 3 insulin molecules bound, 2 to site 1 and 1 to site 2
r1x22	active receptor state with 3 insulin molecules bound, 1 to site 1 and 2 to site 2
r1x22d	active receptor state with 1 insulin molecules bound to site 1 and an insulin dimer to site 2
r11x22	active receptor state with 4 insulin molecules bound, 2 to site 1 and 2 to site 2

<u>The internalization process</u> We included internalization in the insulin binding model to be able to relate the insulin binding level with the adipose tissue level. This part is based the *Mifa* model in (2).

d/dt(rend) = -R37+R44 d/dt( <b>rendP</b> ) = -R44+R39+R40+R41	rend(0) = 3.31712e-05 rendP(0) = 0.0002125
+R42+R43+R48	
d/dt(iendIR) = +R39+2*R40+2*R41	iendIR(0) = 7.25519e-06
+3*R42+3*R43-R45	
d/dt(iend) = -R38+R45	iend(0) = 1.13228e-06
d/dt(rPbasal) = R46 - R47 - R48	rPbasal(0) = 3.87230e-05

internalized receptor states
internalized and phosphorylated receptor states
receptor bound internalized insulin molecules
internalized insulin molecules
state that account for the basal phosphorylation of receptor states

#### Reactions

Here all reactions of the insulin binding level are gathered. Most of the reactions follow simple mass action kinetics, but R44 and R45 that belong to our addition of internalization are saturated. These reactions describe the action of a feedback from a downstream signaling intermediate  $(X_P)$  and these equations are based on (2). All other reactions are from Kiselyov *et al.* (4).

R1 = 2*a1*S1*r0	R26 = d2*r11x2
	R20 = d2 r11 R2 R27 = d2*r1 x22
	$R_{28} = d1*r11x2$
	$R_{20} = d1^{+}r_{1}r_{2}$ $R_{29} = d1^{+}r_{1}r_{2}$
	R30 = a1*S1*r1x22
	R31 = a2*S1*r11x2
R7 = a2*S1*r2	R32 = K4*S1*r1x22
$R8 = d2 \star r2$	R33 = K8*r1x22d
R9 = Kcr*r1	R34 = d2*r1x22d
R10 = Kcr*r2	R35 = d1*r11x22
R11 = a1*S1*r1x2	R36 = d2*r11x22
R12 = 2*d1*r11	R37 = Kex*rend
R13 = d1*r12	R38 = Kex*iend
R14 = a2*S1*r1x2	R39 = (Kend)*r1x2
R15 = d2*r12	R40 = (Kend) * r11x2
R16 = 2*d2*r22	R41 = (Kend) * r1x22
R17 = 2*Kcr*r11	R42 = (Kend) * r1x22d
R18 = Kcr*r12	R43 = (Kend) * r11x22
R19 = d2*r1x2	$R44 = (Kdp+Kcat*(X_P) /$
R20 = Kcr*r12	(Km+( <b>X_P</b> )))*rendP
R21 = 2*Kcr*r22	R45 = (Kdp+Kcat*( <b>X_P</b> )/
R22 = d1*r1x2	(Km+( <b>X_P</b> )))*iendIR
R23 = a2*S2*r1x2	R46 = kfbasal*r0
R24 = d1*r11x2	R47 = krbasal*rPbasal
R25 = d2*r1x22	R48 = Kend*rPbasal

#### Variables

The variables S1 and S2 describe the interstitial concentration of insulin as a monomer (S1) and as a dimer (S2) in molars. The dimer will not form in the low insulin concentrations in the physiological situation.

S1 = (**INS**+5)\*1e-12 S2 = 0

#### Parameters

For two of the parameters, K4 and K8, we used the values from (4), and for the others we used optimization to find the acceptable values.

K4 = 1400 K8 = 0.01

al	a2	d1	d2	Kcr	Kex
Kend	Kdp	Kcat	Km	kfbasal	krbasal

#### References

- 1. Sedaghat, A. R., Sherman, A., and Quon, M. J. (2002) *Am J Physiol Endocrinol Metab* **283**, E1084-1101
- 2. Brännmark, C., Palmer, R., Glad, S. T., Cedersund, G., and Strålfors, P. (2010) *J Biol Chem* **285**, 20171-20179
- 3. Dalla Man, C., Rizza, R. A., and Cobelli, C. (2007) *IEEE Trans Biomed Eng* 54, 1740-1749
- 4. Kiselyov, V. V., Versteyhe, S., Gauguin, L., and De Meyts, P. (2009) *Mol Syst Biol* 5, 243